** Shares of drug developer Alnylam Pharmaceuticals ALNY.O rise 6.5% to $270 premarket
** On Thursday, US FDA approved ALNY's injectable drug, Amvuttra, to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and deadly heart disease
** Amvuttra was first approved in 2022 to treat nerve damage related to ATTR-CM
** Amvuttra is the first treatment to address both nerve and heart forms of ATTR-CM, working by reducing production of the disease-causing protein
** List price of Amvuttra is $119,351 per prefilled syringe, administered every 3 months, with no planned change for ATTR-CM treatment
** Brokerage Jefferies said it expects Amvuttra's price to decrease over time as prescription volumes rise, with initial impacts likely in the H2 of this year
** ALNY gained 71.4%, in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。